Newborn fungal infection study tests two drugs head-to-head
NCT ID NCT02145832
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study compared two antifungal drugs, fluconazole and micafungin, in 100 newborns with suspected or confirmed candidiasis. The goal was to see if micafungin works as well as the standard treatment fluconazole and to check their safety. The study also looked at how the drugs behave in the bodies of growing premature and full-term infants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fluconazole and micafungin
- What this could lead to
- If successful, this could show that micafungin is a safe and effective alternative to fluconazole for treating fungal infections in newborns.
- What could go wrong
- This is a completed Phase 2/3 trial with only 100 participants, so results may not apply to all newborns. The study compares two existing drugs, so no breakthrough is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANDIDIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Antwerp, Rocourt, Liège, Louvain, Namur, Belgium
-
Study site
Paris, Lyon, Saint-Pierre de La Réunion, France
-
Study site
Roma, Torino, Catania, Foggia, Reggio Emilia, Italy
-
Study site
Rotterdam, Amsterdam, Utrecht, Isala, Netherlands
-
Study site
Malaga, Salamanca, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.